Clinical results published in the New England Journal of Medicine show the investigational gene regulation therapy zorevunersen produced large seizure reductions and functional improvements in children and adolescents with Dravet syndrome. In open‑label and dose‑escalation cohorts, treated patients experienced between 59% and 91% fewer seizures compared with baseline over follow‑up windows, with most adverse events rated mild to moderate. The multicenter program—led by teams at University College London and Great Ormond Street Hospital—targets the SCN1A genetic defect that underlies the majority of Dravet cases and represents one of the most advanced gene‑targeting attempts to treat a severe pediatric epilepsy. Researchers reported gains in day‑to‑day functioning alongside seizure declines, and ongoing randomized phase 3 trials will probe durability and broader efficacy. If confirmatory trials replicate these results, zorevunersen would mark a rare example of a therapy addressing a monogenic neurodevelopmental disorder’s root cause rather than only symptom control, with implications for regulatory pathways, pediatric trial design, and commercialization strategy in rare neurologic diseases.